大成生化(00809.HK)終止向第三方配股
大成生化(00809.HK)今年1月曾宣布,向獨立第三方睿烜發行17.81億股新股,籌集約2.4億元。公司公布,經計及近期市況及自訂立認購協議起已經過相當長一段時間後,原有的所得款項時間表及擬定用途已經失效及無效,已嘗試與認購方就變更所得款項用途磋商,惟雙方未能達成共識。因此於10月10日訂立終止協議。
大成生化表示,除目前透過推進落實債務重組計劃及徵收位於長春市綠園區的土地及物業,以改善財務狀況的計劃外,董事會將致力積極尋求與不同的業內人士或潛在投資者進行合作及投資的其他機會,從而加強財務狀況及業務組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.